December 5, 2016
Trial to Test Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab) EAGAN, MN — December 5, 2016 — Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and Canada) to include a Phase 2 clinical study investigating Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in second- and third-line patients...
Read More
November 11, 2016
3 Poster Presentations Scheduled for Society for Immunotherapy of Cancer Annual Meeting EAGAN, MN — November 11, 2016 — Biothera Pharmaceuticals, Inc. will present new preclinical data today that further validate the ability of its Phase 2 cancer immunotherapy drug Imprime PGG to induce coordinated innate and adaptive immune responses that may enhance the efficacy of checkpoint inhibitor therapies. The data will be highlighted in three...
Read More
November 7, 2016
Formation of Imprime PGG-Immune Complex Essential to Anti-Tumor Activity EAGAN, MN — November 7, 2016 — Biothera Pharmaceuticals, Inc. today announced the publication of preclinical research identifying an essential mechanism in the activation of anti-cancer immune responses by Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug. The formation of an immune complex between Imprime PGG and endogenous anti-beta glucan antibodies (ABA) offers the potential...
Read More
September 27, 2016
Clinical findings presented at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference EAGAN, MN — September 27, 2016 — Biothera Pharmaceuticals, Inc. today announced the presentation of clinical data demonstrating the mechanism of action of Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug, in healthy human volunteers. These are the first data to show that when administered intravenously to healthy human subjects, Imprime PGG drives the immunopharmacodynamic...
Read More
August 24, 2016
Biothera’s Imprime PGG and Merck’s anti-PD-1 inhibitor KEYTRUDA® (pembrolizumab) to be evaluated in combination for patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans to initiate a Phase 1b/2 Imprime PGG/KEYTRUDA trial in patients with non-small cell lung cancer (NSCLC) EAGAN, MN — August 24, 2016 — Biothera Pharmaceuticals, Inc. today announced...
Read More
August 3, 2016
EAGAN, MN — August 3, 2016 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 11:30 a.m. Eastern Time in Boston, Mass. Mr. Labinger will provide an overview of Biothera Pharmaceuticals and a business update. About Biothera Pharmaceuticals, Inc.Biothera Pharmaceuticals is a privately held biotechnology company...
Read More
May 31, 2016
EAGAN, MN — May 31, 2016 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the Sachs Associates 2nd Annual Immuno-Oncology BD&L and Investment Forum on Friday, June 3, 2016 at 2:30 p.m. Central Time in Chicago. Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology, which include the initiation of three Phase...
Read More
April 18, 2016
EAGAN, MN — April 18, 2016 — Biothera Pharmaceuticals, Inc. today announced research providing new insights into the ability of the Company’s Phase 2 cancer immunotherapy to coordinate innate and adaptive immune responses and enhance the effectiveness of combination therapies. The findings were presented today at the AACR annual meeting, which is taking place in New Orleans, LA, April 16-20, 2016. The company is presenting...
Read More
April 4, 2016
EAGAN, MN — April 4, 2016 — Biothera Pharmaceuticals, Inc. today announced that Barry Labinger, Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8, 2016 at 1:15p.m. Eastern Time in Boston, Mass. Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology. About Biothera Pharmaceuticals, Inc.Biothera Pharmaceuticals is a privately held biotechnology company...
Read More
March 10, 2016
EAGAN, MN — March 10, 2016 — Biothera Pharmaceuticals Inc. today will present data on its Phase 2 cancer immunotherapy Imprime PGG, the Company’s first-in-class, systemically administered beta glucan PAMP (Pathogen Associated Molecular Patterning molecule) at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference 2016, taking place at the Moscone Convention Center, San Francisco. Jeremy Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera...
Read More